INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGITIS
Provided herein are compositions and related methods useful for prevention or mitigation of ionizing radiation-induced esophagitis. The compositions comprise compounds comprising a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent or mitigate esophageal damage caused by radiation.
1 . A method of preventing or mitigating ionizing irradiation-induced esophagitis in a subject, comprising administering to the esophagus of a subject prior to, during or after exposure of the subject to radiation, a composition comprising an amount of a compound effective to prevent, mitigate or treat radiation injury in the subject; wherein the compound is chosen from one of:
wherein X is one of
R 1 and R 2 are hydrogen, C 1 -C 6 straight or branched-chain alkyl, or a C 1 -C 6 straight or branched-chain alkyl further comprising a phenyl(C 6 H 5 ) group, that is unsubstituted or is methyl-, hydroxyl-, chloro- or fluoro-substituted; R 4 is hydrogen, C 1 -C 6 straight or branched-chain alkyl, or a C 1 -C 6 straight or branched-chain alkyl further comprising a phenyl(C 6 H 5 ) group, that is unsubstituted or is methyl-, hydroxyl-,chloro- or fluoro-substituted; R 3 is —NH—R 5 , —O—R 5 or —CH 2 —R 5 , and R 5 is an —N—O., —N—OH or N═O containing group; R is —C(O)—R 6 , —C(O)O—R 6 , or —P(O)—(R 6 ) 2 wherein R 6 is C 1 -C 6 straight or branched-chain alkyl or C 1 -C 6 straight or branched-chain alkyl further comprising one or more phenyl (—C 6 H 5 ) groups that are independently unsubstituted, or methyl-, ethyl-, hydroxyl-, chloro- or fluoro-substituted;
c). a compound having the structure (i) R1-R2-R3 or (ii) R1, in which R1 and R3 are the same or different and have the structure —R4-R5, in which R4 is a mitochondria targeting group and R5 is —NH—R6, —O—R6 or —CH 2 —R6, wherein R6 is an —N—O., —N—OH or N═O containing group and R4 and R5 for each of R1 and R3 may be the same or different; and R2 is a linker; and
wherein X is one of
R 1 is hydrogen, C 1 -C 6 straight or branched-chain alkyl, or a C 1 -C 6 straight or branched-chain alkyl further comprising a phenyl(C 6 H 5 ) group, that is unsubstituted or is methyl-, hydroxyl-, chloro- or fluoro-substituted; R 4 is hydrogen, C 1 -C 6 straight or branched-chain alkyl, or a C 1 -C 6 straight or branched-chain alkyl further comprising a phenyl(C 6 H 5 ) group, that is unsubstituted or is methyl-,hydroxyl-, chloro- or fluoro-substituted; R 3 is —NH—R 5 , —O—R 5 or —CH 2 —R 5 , and R 5 is an —N—O., —N—OH or N═O containing group; and R is —C(O)—R 6 , —C(O)O—R 6 , or —P(O)—(R 6 ) 2 , wherein R 6 is C 1 -C 6 straight or branched-chain alkyl or C1-C6 straight or branched-chain alkyl further comprising one or more phenyl (—C 6 H 5 ) groups that are independently unsubstituted, or methyl-, ethyl-, hydroxyl-, chloro- or fluoro-substituted.
2 . The method of claim 1 , the compound having the structure
or the structure
3 . The method of claim 2 , the compound having the structure
4 . The method of claim 3 , the compound having the structure
5 . The method of claim 1 , the compound having the structure
in which R is Ac, Boc, Cbz, or —P(O)-Ph 2 .
6 . The method of claim 1 , the compound having the structure
7 . The method of claim 1 , the compound having the structure
in which R 1 , R 2 , R 4 , and R 6 are independently chosen from hydrogen, methyl, ethyl, propyl, 2-propyl, butyl, t-butyl, pentyl, hexyl, benzyl, hydroxybenzyl, phenyl and hydroxyphenyl.
8 . The method of claim 1 , the compound having the structure
wherein when X is —CH═CR 4 —, R 4 is hydrogen, methyl or ethyl.
9 . The method of claim 1 , the compound having the structure
in which R 5 is 2,2,6,6-Tetramethyl-4-piperidine 1-oxyl, 1-methyl azaadamantane N-oxyl, or 1,1,3,3-tetramethylisoindolin-2-yloxyl.
10 . The method of claim 1 , the compound having the structure
or the structure
in which R is —NH—R 1 , —O—R 1 or —CH 2 —R 1 , and R 1 is an —N—O., —N—OH or N═O containing group.
11 . The method of claim 1 , the compound having the structure
in which R1, R2 and R3 are, independently, hydrogen, C 1 -C 6 straight or branched-chain alkyl, or C 1 -C 6 straight or branched-chain alkyl including a phenyl(C 6 H 5 ) group that is unsubstituted, methyl-, hydroxyl-, chloro- or fluoro-substituted; R4 is an —N—O., —N—OH or N═O containing group; and R is —C(O)—R5, —C(O)O—R5, or —P(O)—(R5) 2 , wherein R5 is C 1 -C 6 straight or branched-chain alkyl, or C 1 -C 6 straight or branched-chain alkyl including a phenyl(Ph,C 6 H 5 ) group that is unsubstituted, methyl-, hydroxyl-, chloro- or fluoro-substituted.
12 . The method of claim 11 , in which R is Ac, Boc, Cbz, or —P(O)-Ph 2 .
13 . The method of claim 11 in which R1, R2 and R3 independently are methyl, ethyl, propyl, 2-propyl, butyl, t-butyl, pentyl, hexyl, benzyl, hydroxybenzyl, phenyl and hydroxyphenyl.
14 . The method of claim 11 , in which R4 is 2,2,6,6-Tetramethyl-4-piperidine 1-oxyl, 1-methylazaadamantane N-oxyl), or 1,1,3,3-tetramethylisoindolin-2-yloxyl.
15 - 20 . (canceled)
21 . The method of claim 1 , the compound having the structure:
22 . The method of claim 1 , the compound having the structure:
23 . The method of claim 1 , the compound having the structure:
24 - 26 . (canceled)
27 . The method of claim 1 , in which the compound is selected from the group consisting of: XJB-5-131, XJB-5-125, XJB-5-197, XJB-7-53, XJB-7-55, XJB-7-75, JP4-049, XJB-5-208, JED-E71-37, JED-E71-58.
28 . The method of claim 1 , in which the amount effective to prevent or mitigate ionizing irradiation-induced esophagitis in the subject ranges from 0.1 to 100 mg/kg in the subject.
29 - 31 . (canceled)
32 . The method of claim 1 , in which the compound is administered between 30 minutes and one hour after radiation exposure in the subject.
33 . The method of claim 1 , in which the compound is administered prior to radiation exposure in the subject.
34 . The method of claim 1 in which the compound is formulated in an oral liquid dosage form.
35 . The method of claim 34 , in which the oral liquid dosage form is a multi-phase liquid.
36 . The method of claim 35 , in which the multi-phase liquid is a liposome preparation.
37 . The method of claim 35 in which the multi-phase liquid preparation comprises the compound, a phospholipid, a non-ionic surfactant, a cationic lipid and an aqueous solvent.
38 . The method of claim 37 , in which the cationic lipid is selected from the group consisting of DC-Cholesterol, DOTAP, DODAP, DDAB, ethyl-PC, DOTMA, and mixtures thereof.
39 . The method of claim 35 in which multi-phase liquid comprises the compound, a phosphatidyl choline, a non-ionic detergent, a cationic lipid and an aqueous solvent.
41 - 49 . (canceled)
50 . A multi-phase or liposome composition comprising:
(a) a compound chosen from one of:
wherein X is one of
R 1 and R 2 are hydrogen, C 1 -C 6 straight or branched-chain alkyl, or a C 1 -C 6 straight or branched-chain alkyl further comprising a phenyl(C 6 H 5 ) group, that is unsubstituted or is methyl-, hydroxyl-, chloro- or fluoro-substituted; R 4 is hydrogen, C 1 -C 6 straight or branched-chain alkyl, or a C 1 -C 6 straight or branched-chain alkyl further comprising a phenyl(C 6 H 5 ) group, that is unsubstituted or is methyl-, hydroxyl-, chloro- or fluoro-substituted; R 3 is —NH—R 5 , —O—R 5 or —CH 2 R 5 , and R 5 is an —N—O., —N—OH or N═O containing group; R is —C(O)—R 6 , —C(O)O—R 6 , or —P(O)—(R 6 ) 2 , wherein R 6 is C 1 -C 6 straight or branched-chain alkyl or C 1 -C 6 straight or branched-chain alkyl further comprising one or more phenyl (—C 6 H 5 ) groups that are independently unsubstituted, or methyl-, ethyl-, hydroxyl-, chloro- or fluoro-substituted;
iii) a compound having the structure (i) RI—R2-R3 or (ii) R1 in which R1 and R3 are the same or different and have the structure —R4-R5, in which R4 is a mitochondria targeting group and R5 is —NH—R6, —O—R6 or —CH 2 —R6, wherein R6 is an —N—O., —N—OH or N═O containing group and R4 and R5 for each of R1 and R3 may be the same or different; and R2 is a linker; and
wherein X is one of
R 1 is hydrogen, C 1 -C 6 straight or branched-chain alkyl, or a C 1 -C 6 straight or branched-chain alkyl further comprising a phenyl(C 6 H 5 ) group, that is unsubstituted or is methyl-, hydroxyl-, chloro- or fluoro-substituted; R 4 is hydrogen, C 1 C 6 straight or branched-chain alkyl, or a C 1 -C 6 straight or branched-chain alkyl further comprising a phenyl(C 6 H 5 ) group, that is unsubstituted or is methyl-, hydroxyl-, chloro- or fluoro-substituted; R 3 is —NH—R 5 , —O—R 5 or —CH 2 —R 5 , and R 5 is an —N—O., —N—OH or N═O containing group; and R is —C(O)—R 6 , —C(O)O—R 6 , or —P(O)—(R 6 ) 2 , wherein R 6 is C 1 -C 6 straight or branched-chain alkyl or C 1 -C 6 straight or branched-chain alkyl further comprising one or more phenyl (—C 6 H 5 ) groups that are independently unsubstituted, or methyl-, ethyl-, hydroxyl-, chloro- or fluoro-substituted;
(b) a phospholipid;
(c) a non-ionic detergent;
(d) a cationic lipid; and
(e) an aqueous solvent.
51 . The composition of claim 50 , consisting essentially of the compound, a phospholipid, a non-ionic detergent a cationic lipid and the aqueous solvent.
52 . The composition of claim 51 , in which the cationic lipid is a glutamic acid dialkyl amide.
53 . The composition of claim 52 , in which in which the glutamic acid dialkyl amide is L-glutamic acid-1,5-dioleyl amide.
54 . The composition of claim 51 , in which the phospholipid is a phosphatidyl choline.
55 - 56 . (canceled)
57 . The composition of claim 50 , consisting essentially of the compound, soy phosphatidyl choline, L-glutamic acid-1,5-dioleyl amide, Tween 80 and the aqueous solvent.
58 . A multiphase or liposome composition consisting essentially of soy phosphatidyl choline, Tween 80, L-glutamic acid-1,5-dioleyl amide (approximately 4:1:1 w/w), and an aqueous solvent with 8 mg/ml JP4-039.
59 - 61 . (canceled)